This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| European Pharmacovigilance Risk Assessment Committee | |
|---|---|
| Name | European Pharmacovigilance Risk Assessment Committee |
| Formation | 2012 |
| Predecessor | Committee for Medicinal Products for Human Use |
| Purpose | Pharmacovigilance and risk assessment for medicinal products |
| Headquarters | Amsterdam |
| Region | European Union |
| Parent organisation | European Medicines Agency |
European Pharmacovigilance Risk Assessment Committee The European Pharmacovigilance Risk Assessment Committee is a scientific committee responsible for evaluating pharmacovigilance data, assessing safety signals, and recommending regulatory actions for medicinal products within the European Union. It operates within a framework that connects pharmacovigilance reporting from national competent authorities such as the Medicines and Healthcare products Regulatory Agency, agencies like the Federal Institute for Drugs and Medical Devices, and international bodies including the World Health Organization and the International Council for Harmonisation. The committee’s opinions inform decisions by EU institutions such as the European Commission, the Council of the European Union, and the European Parliament, and have influenced policy debates in member states including Germany, France, Italy, Spain, and Poland.
The committee’s mandate derives from EU legal instruments including the Directive 2001/83/EC, Regulation (EC) No 726/2004, and subsequent pharmacovigilance legislation adopted after incidents such as the Vioxx controversy and debates following the Thalidomide scandal. It assesses safety signals from sources like spontaneous reporting systems used by the Yellow Card scheme, the EudraVigilance database, and post-authorisation safety studies commissioned under procedures related to the European Commission and the Council of the European Union. Its remit intersects with international regulators such as the United States Food and Drug Administration, the Pharmaceutical and Medical Devices Agency (Japan), and the Swissmedic authority, and with global initiatives led by the World Health Organization and the Council of Europe.
The committee was established following reforms to EU pharmacovigilance prompted by safety controversies involving products regulated in markets including the United Kingdom, United States, and France. Early pharmacovigilance coordination had relied on the Committee for Medicinal Products for Human Use and national pharmacovigilance centres such as the Agence nationale de sécurité du médicament et des produits de santé and the Bundesinstitut für Arzneimittel und Medizinprodukte. Legislative milestones that shaped the committee include European Commission proposals debated in the European Parliament and adopted by the Council of the European Union, building on guidelines from the International Council for Harmonisation and case studies from the European Centre for Disease Prevention and Control. The committee’s early work responded to signals from medicines approved under procedures involving the European Commission and referrals that involved stakeholders such as patient advocacy groups and health technology assessment bodies like NICE.
Membership comprises representatives appointed by EU member states, experts nominated by competent authorities including Agencia Española de Medicamentos y Productos Sanitarios, Agenzia Italiana del Farmaco, and the Läkemedelsverket (Sweden), and patient and healthcare professional representatives similar to those engaged by the European Patients' Forum and European Hospital and Healthcare Federation. The committee interfaces with specialised working groups that include pharmacovigilance assessors drawn from agencies such as Medicines and Healthcare products Regulatory Agency and Federal Institute for Drugs and Medical Devices. Chairs and rapporteurs have sometimes included figures with academic affiliations at institutions like University of Oxford, Karolinska Institutet, Universität Heidelberg, and Université Paris-Saclay. Administrative support is provided by the European Medicines Agency, whose Executive Director has had oversight roles akin to those seen in agencies such as European Environment Agency.
Core functions include signal detection, risk assessment, recommendations for risk minimisation measures, and review of periodic safety update reports for products authorised via the centralised procedure. Procedures involve sources such as reports from marketing authorisation holders, safety data generated in regulatory contexts exemplified by the centralised marketing authorisation decisions, and collaboration with registries like those used in clinical networks associated with European Respiratory Society and European Society of Cardiology. The committee employs methodologies influenced by regulatory science from bodies like the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance and statistical standards promoted by organisations such as the European Society for Medical Oncology. It uses public hearings and stakeholder consultations similar to practices in European Medicines Agency scientific committees and coordinates with ethics frameworks referenced by institutions like the European Research Council.
Decisions are issued as scientific opinions, recommendations for regulatory action, or referrals to the European Commission for legally binding measures under instruments like Regulation (EC) No 726/2004. Outputs include advice on product information updates, measures such as restricted indications, additional monitoring symbols used by national lists like those maintained by Agence nationale de sécurité du médicament et des produits de santé, and recommendations for pharmacovigilance plans and post-authorisation safety studies involving collaborations with agencies such as Agence Nationale de Sécurité Sanitaire de l'Alimentation, de l'Environnement et du Travail and Fimea (Finland). The committee’s opinions have informed legal decisions comparable to those navigated by the Court of Justice of the European Union in regulatory disputes.
As a committee of the European Medicines Agency, it reports through EMA governance structures to the European Commission and liaises with the European Parliament and the Council of the European Union on pharmacovigilance policy. It collaborates with EMA committees including the Committee for Medicinal Products for Human Use and the Paediatric Committee, and coordinates with the Pharmacovigilance and Risk Management Committee’s counterparts in non-EU jurisdictions like the FDA and Health Canada. The committee’s work fits into wider EU public health strategies coordinated with agencies such as the European Centre for Disease Prevention and Control and interacts with member-state competent authorities, industry stakeholders represented by trade associations such as European Federation of Pharmaceutical Industries and Associations, and patient organisations like European Patients' Forum.
Notable assessments have addressed safety concerns for therapeutic classes with high public visibility including vaccines authorised after procedures used by the European Commission, biologics evaluated alongside guidance from the European Directorate for the Quality of Medicines & HealthCare, and medicines subject to high-profile referrals similar to cases from France and Germany. The committee’s opinions have led to label changes, risk minimisation measures, and enhanced monitoring for products involved in controversies comparable to historical cases cited in regulatory reviews by the European Court of Auditors and influenced pharmacovigilance capacity-building efforts across member states like Spain and Italy. Its impact extends to shaping pharmacovigilance science discussed in scientific forums such as events organised by the European Clinical Research Infrastructure Network and publications by researchers affiliated with institutions like Karolinska Institutet and University College London.
Category:European Medicines Agency Category:Pharmacovigilance